Naranjo, A.
Ojeda, S.
Giner, M.
Balcells-Oliver, M.
Canals, L.
Cancio, J. M.
Duaso, E.
Mora-Fernández, J.
Pablos, C.
González, A.
Lladó, B.
Olmo, F. J.
Montoya, M. J.
Menéndez, A.
Prieto-Alhambra, D.
Article History
Received: 14 September 2019
Accepted: 22 January 2020
First Online: 25 April 2020
Compliance with ethical standards
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Naranjo A has received research grants from Amgen, consulting fees from UCB and has participated in speakers’ bureaus for Amgen and Lilly. Ojeda S has received research grants from Amgen. Canals L and Balcells-Oliver M work at Amgen and hold stock in Amgen. Mora-Fernández J has received research grants from Amgen and consulting fees from Amgen, Lilly, and UCB-Pharma. Lladó B has received fees as a speaker at medical sessions and meetings for Amgen and UCB, and as a speaker at medical sessions for Lilly. Olmo FJ has received consulting fees from Amgen, UCB and Abbott. Prieto-Alhambra D has received research Grants from Amgen, UCB Biopharma and Les Laboratoires Servier, and non-remunerative positions; the department has received fees for consultancy services from UCB Biopharma and for speaker and advisory board membership services from Amgen. Giner M, Cancio JM, Duaso E, Montoya MJ, Pablos C, González A, and Menéndez A declare no conflict of interests.